Sulzer Medica/Tutogen Medical
This article was originally published in The Gray Sheet
Executive Summary
Sulzer increases stake in bioimplants maker Tutogen through Nov. 17 deal with Capital Partners II, under which Sulzer will purchase up to 50% of beneficiaries' interests in Capital Partners for about $30 mil. (21,627 trust units at $1,387 each). Capital Partners owns more than 50% of Tutogen. Sulzer already has a stake of almost 10% in Tutogen, and markets the firm's bone tissue products for spinal and dental applications. If Sulzer is offered fewer than 8,651 trust units, then the firm will have no obligation to complete the deal, Sulzer notes. Tender offer is valid for at least 20 working days
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.